Hot Stocks

The stock market changes from minute to minute, and what’s hot today may not be hot tomorrow. Our expert analysts spot hot stocks that are heating up before the crowd swoops in to bid prices higher, and our journalists sift through the noise to shine a light on trending investments -- in spaces ranging from quantum computing to marijuana stocks -- to determine whether they’re actually worth your time.

Gold Back Above $1,600 on Positive Housing, Euro Zone News

By Andrew Burger, InvestorPlace Contributor
Gold and silver were headed higher Tuesday morning. Miners were surging as well, with Coeur d'Alene Mines and Hecla Mining making aggressive moves.

Buffett Got Burned on Bank of America, and There’s No Bottom in Sight

By Jeff Reeves
Bank of America plummeted below the $5 mark on Monday, but you're not going to hear many people calling it a value stock -- and rightfully so.

Investors Need to Dig Into the Bakken Shale

By Aaron Levitt, InvestorPlace Contributor
The huge oil deposits in North Dakota and Montana could be portfolio-changing investments for those who bet early on the right players.

Bank of America Falls Below $5 — Monday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger
BofA's latest slide continues, leading big banks like Citi, JPMorgan, Goldman and Wells Fargo lower. Also, AT&T announces it will end its bid for T-Mobile USA.

Gold Flat, Silver Sliding in Monday Trading

By Andrew Burger, InvestorPlace Contributor
Precious metal trusts, miners were heading lower in a broad range during Monday morning trading. Also, Eldorado Gold announces deal to buy European Gold Fields.

Amgen CEO Says ‘I’m Leaving.’ Investors Say ‘Good Riddance’

By Barry Cohen, Health Care Writer
After a decade as CEO, the oft-maligned Kevin Sharer will step down. That's giving shareholders holiday cheer as they bid the stock up on the news.

RIMM Completes a Week of Gloomy Outlooks — Friday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger
Research In Motion joined Intel, Best Buy and First Solar in forecasting leaner times ahead. Here's a look at RIM, as well as other big news from this week.

Researcher: J&J/Pharmacyclics Drug Could Be a Game-Changer

By Barry Cohen, Health Care Writer
The experimental cancer drug Johnson & Johnson bought last week is receiving high praise, and could be "paradigm-shifting."

Despite Record Orders, Boeing’s McNerney Could Be Ejected

By Susan J. Aluise, Aviation, Auto & Transportation Writer
James McNerney's uneven tenure could be over soon. Would Ford's Alan Mulally move in? Plenty of folks are rooting for the former Boeing exec's return.

Warm Up to Newmont Mining’s Golden Touch

By Richard Band
The recent selloff in gold should abate in the next few weeks. For now, a few mining stocks -- and Newmont in particular -- look extremely undervalued.

Precious Metals, Miners Recover With Unchanged U.S. CPI

By Andrew Burger, InvestorPlace Contributor
Metal prices rise, and miners like NovaGold and Silver Standard Resources boomed Friday. Gold, silver still were heavily down for the week, however.

The Sun Also Rises for Solar Stocks

By Jim Woods, Editor-in-Chief, Successful Investing, Intelligence Report, Bullseye Stock Trader
The latest plunge looks grim for solar stocks, but a few bits of info lost between the headlines could point to better times ahead -- making now the time to buy.

5 Best and Worst S&P 500 Stocks of 2011

By Jim Woods, Editor-in-Chief, Successful Investing, Intelligence Report, Bullseye Stock Trader
In what was an extremely volatile year for the market, it might come as no surprise that the S&P 500 saw some really big winners — and some even bigger losers. Here are 2011's best and worst performers.

The Danger of Investing in Retail Stocks

By Lawrence Meyers, InvestorPlace Contributor
When it comes to investing in retail, slow and steady wins the race. Avoid companies like these crash-and-burn victims.

FedEx Flies, Discover Dives — Thursday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger
Both beat earnings estimates, but then went separate ways.

Covidien Follows Abbott With a Pharma Spin-Off

By Barry Cohen, Health Care Writer
Could Sanofi, Novartis or GlaxoSmithKline be next to separate pharmaceutical development into a stand-alone company?

A Double Whammy for Homebuilders

By Ethan Roberts, InvestorPlace Contributor
A downgrade of TOL and LEN, then a downbeat announcement from the National Association of Realtors raise big questions.

Gold, Silver Continue Their Slump

By Andrew Burger, InvestorPlace Contributor
Positive economic data can't get precious metals rallying, as European concerns continue their grip on risk assets.

The ‘Other Berkshire’ Worth a Closer Look

By Lawrence Meyers, InvestorPlace Contributor
Its operation can be difficult to grasp, but if you know what to look for, you'll get a better understanding for this smartly run company.
Load More Articles